Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (4): 795-800.DOI: 10.19852/j.cnki.jtcm.2023.04.002
Previous Articles Next Articles
Effectiveness of bee venom acupuncture for patients suffering from periarthritis humeroscapularis
Minh Duc Nguyen1, Thanh Van Tran2, Quoc Vinh Nguyen3, Cay Doan Ha4, Linh Vu Phuong Dang5(
)
- 1 Senior Specialist Clinic, National Hospital of Acupuncture, Hanoi 1000, Vietnam
2 Department of Senior Specialist National Hospital of Acupuncture, Hanoi 1000, Vietnam
3 Department of Senior Specialist, Military Institute of Traditional Medicine, Hanoi 1000, Vietnam
4 Department of minimally invasive spine, National Hospital of Acupuncture, Hanoi 1000, Vietnam
5 Department of Medicine, Dai Nam University, Hanoi 1000, Vietnam
-
Received:2022-01-11Accepted:2022-06-15Online:2023-08-15Published:2023-07-03 -
Contact:Dr. Linh Vu Phuong Dang, Department of Medicine, Dai Nam University, Hanoi 1000, Vietnam. phuonglinh.j@gmail.com. Telephone: +84-974782904
Cite this article
Minh Duc Nguyen, Thanh Van Tran, Quoc Vinh Nguyen, Cay Doan Ha, Linh Vu Phuong Dang. Effectiveness of bee venom acupuncture for patients suffering from periarthritis humeroscapularis[J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 795-800.
share this article
Table 1 General characteristics of patients participated in the study ($\bar{x}±s$)
| Item | BV1 (n = 30) | BV2 (n = 30) | BV3 (n = 30) | CT (n = 30) | |
|---|---|---|---|---|---|
| Age (years) | 53±9 | 54±10 | 53±9 | 53±9 | |
| Gender (M, F) (n) | 12, 18 | 14, 16 | 11, 19 | 14, 16 | |
| Duration (months) [n (%)] | |||||
| < 1 month | 9 (30) | 13 (43.33) | 10 (33.33) | 14 (46.67) | |
| 1-3 months | 9 (30) | 9 (30) | 13 (43.33) | 8 (26.67) | |
| > 3 months | 12 (40) | 8 (26.67) | 7 (23.33) | 8 (26.67) | |
Table 1 General characteristics of patients participated in the study ($\bar{x}±s$)
| Item | BV1 (n = 30) | BV2 (n = 30) | BV3 (n = 30) | CT (n = 30) | |
|---|---|---|---|---|---|
| Age (years) | 53±9 | 54±10 | 53±9 | 53±9 | |
| Gender (M, F) (n) | 12, 18 | 14, 16 | 11, 19 | 14, 16 | |
| Duration (months) [n (%)] | |||||
| < 1 month | 9 (30) | 13 (43.33) | 10 (33.33) | 14 (46.67) | |
| 1-3 months | 9 (30) | 9 (30) | 13 (43.33) | 8 (26.67) | |
| > 3 months | 12 (40) | 8 (26.67) | 7 (23.33) | 8 (26.67) | |
Table 2 Average of VAS scores and β-Endorphin levels among groups at baseline, 10 and 15 d after treatment initiation ($\bar{x}±s$)
| Item | Baseline | 10 d | 15 d | aP value |
|---|---|---|---|---|
| VAS | ||||
| BV1 | 5.5±0.9 | 3.6±0.8 | 2.5±0.6 | <0.01 |
| BV2 | 5.5±0.9 | 3.5±0.7 | 2.5±0.7 | <0.01 |
| BV3 | 5.5±1.0 | 2.9±0.7 | 1.7±0.7 | <0.01 |
| CT | 5.4±1.0 | 3.9±0.7 | 3.0±0.8 | <0.01 |
| bP value | >0.05 | <0.01 | <0.01 | |
| β-Endorphin | ||||
| BV1 | 837.5±326.5 | 908.9±218.5 | 880.0±194.4 | >0.05 |
| BV2 | 841.1±195.5 | 994.9±285.1 | 912.2±294.8 | >0.05 |
| BV3 | 862.0±182.2 | 1101.2±334.0 | 926.7±219.3 | <0.01 |
| CT | 832.5±228.6 | 878.3±194.6 | 839.9±239.8 | >0.05 |
| bP value | >0.05 | <0.05 | <0.05 | |
Table 2 Average of VAS scores and β-Endorphin levels among groups at baseline, 10 and 15 d after treatment initiation ($\bar{x}±s$)
| Item | Baseline | 10 d | 15 d | aP value |
|---|---|---|---|---|
| VAS | ||||
| BV1 | 5.5±0.9 | 3.6±0.8 | 2.5±0.6 | <0.01 |
| BV2 | 5.5±0.9 | 3.5±0.7 | 2.5±0.7 | <0.01 |
| BV3 | 5.5±1.0 | 2.9±0.7 | 1.7±0.7 | <0.01 |
| CT | 5.4±1.0 | 3.9±0.7 | 3.0±0.8 | <0.01 |
| bP value | >0.05 | <0.01 | <0.01 | |
| β-Endorphin | ||||
| BV1 | 837.5±326.5 | 908.9±218.5 | 880.0±194.4 | >0.05 |
| BV2 | 841.1±195.5 | 994.9±285.1 | 912.2±294.8 | >0.05 |
| BV3 | 862.0±182.2 | 1101.2±334.0 | 926.7±219.3 | <0.01 |
| CT | 832.5±228.6 | 878.3±194.6 | 839.9±239.8 | >0.05 |
| bP value | >0.05 | <0.05 | <0.05 | |
Table 3 Average of degree/point and score of range of motion and shoulder function among groups at baseline, 10 and 15 d after treatment initiation ($\bar{x}±s$)
| Item | Baseline | 10 d | 15 d | aP value | |||||
|---|---|---|---|---|---|---|---|---|---|
| Degree/point | Score | Degree/point | Score | Degree/point | Score | ||||
| Flexion | |||||||||
| BV1 | 100.5±11.47 | 2.40±0.50 | 124.50±17.49 | 3.03±0.49 | 148.33±17.39 | 3.47±0.51 | < 0.01 | ||
| BV2 | 101.17±11.50 | 2.50±0.51 | 136.67±16.47 | 2.87±0.35 | 152.17±10.96 | 3.50±0.51 | < 0.01 | ||
| BV3 | 100.50±11.62 | 2.43±0.50 | 125.67±14.66 | 2.87±0.35 | 147.83±16.33 | 3.57±0.50 | < 0.01 | ||
| CT | 100.50±9.94 | 2.37±0.49 | 131.00±16.89 | 2.87±0.35 | 143.33±12.13 | 3.17±0.38 | < 0.01 | ||
| bP value | >0.05 | >0.05 | >0.05 | >0.05 | <0.05 | <0.05 | |||
| Internal rotation | |||||||||
| BV1 | 58.83±5.52 | 2.17±0.38 | 71.33±5.56 | 2.93±0.25 | 81.13±7.62 | 3.33±0.48 | < 0.01 | ||
| BV2 | 55.67±4.50 | 2.07±0.25 | 67.33±5.04 | 2.93±0.25 | 73,00±5.51 | 3.06±0.25 | < 0.01 | ||
| BV3 | 59.93±5.30 | 2.27±0.45 | 69.67±6.01 | 2.87±0.35 | 79.17±6.54 | 3.17±0.38 | < 0.01 | ||
| CT | 56.17±6.25 | 2.07±0.25 | 68.33±4.61 | 2.93±0.25 | 72.17±5.03 | 2.97±0.18 | < 0.01 | ||
| bP value | >0.05 | >0.05 | >0.05 | >0.05 | <0.05 | <0.05 | |||
| External rotation | |||||||||
| BV1 | 69.53±8.83 | 2.80±0.41 | 79.27±6.78 | 3.17±0.38 | 86.37±3.96 | 3.50±0.51 | < 0.01 | ||
| BV2 | 67.67±4.10 | 2.87±0.35 | 83.50±3.51 | 3.07±0.25 | 88.83±2.52 | 3.80±0.41 | < 0.01 | ||
| BV3 | 67,00±6.10 | 2.73±0.45 | 78,00±6.64 | 3.07±0.25 | 87.50±4.10 | 3.63±0.49 | < 0.01 | ||
| CT | 69.17±4.37 | 2.97±0.18 | 83.50±3.26 | 3.03±0.18 | 87.17±3.13 | 3.50±0.51 | < 0.01 | ||
| bP value | >0.05 | >0.05 | <0.05 | <0.05 | >0.05 | >0.05 | |||
| Shoulder function | |||||||||
| BV1 | 61.70±4.19 | 1.83±0.38 | 74.66±3.65 | 2.73±0.45 | 84.97±4.47 | 3.57±0.50 | < 0.01 | ||
| BV2 | 60.87±4.62 | 1.83±0.38 | 78.57±5.26 | 2.93±0.37 | 89.13±6.51 | 3.73±0.45 | < 0.01 | ||
| BV3 | 61.77±2.99 | 1.93±0.25 | 76,00±2.52 | 2.83±0.38 | 85.60±3.93 | 3.73±0.45 | < 0.01 | ||
| CT | 62.23±5.72 | 1.90±0.40 | 77.80±5.64 | 2.77±0.50 | 86.70±5.88 | 3.60±0.50 | < 0.01 | ||
| bP value | >0.05 | >0.05 | <0.05 | <0.05 | <0.05 | <0.05 | |||
Table 3 Average of degree/point and score of range of motion and shoulder function among groups at baseline, 10 and 15 d after treatment initiation ($\bar{x}±s$)
| Item | Baseline | 10 d | 15 d | aP value | |||||
|---|---|---|---|---|---|---|---|---|---|
| Degree/point | Score | Degree/point | Score | Degree/point | Score | ||||
| Flexion | |||||||||
| BV1 | 100.5±11.47 | 2.40±0.50 | 124.50±17.49 | 3.03±0.49 | 148.33±17.39 | 3.47±0.51 | < 0.01 | ||
| BV2 | 101.17±11.50 | 2.50±0.51 | 136.67±16.47 | 2.87±0.35 | 152.17±10.96 | 3.50±0.51 | < 0.01 | ||
| BV3 | 100.50±11.62 | 2.43±0.50 | 125.67±14.66 | 2.87±0.35 | 147.83±16.33 | 3.57±0.50 | < 0.01 | ||
| CT | 100.50±9.94 | 2.37±0.49 | 131.00±16.89 | 2.87±0.35 | 143.33±12.13 | 3.17±0.38 | < 0.01 | ||
| bP value | >0.05 | >0.05 | >0.05 | >0.05 | <0.05 | <0.05 | |||
| Internal rotation | |||||||||
| BV1 | 58.83±5.52 | 2.17±0.38 | 71.33±5.56 | 2.93±0.25 | 81.13±7.62 | 3.33±0.48 | < 0.01 | ||
| BV2 | 55.67±4.50 | 2.07±0.25 | 67.33±5.04 | 2.93±0.25 | 73,00±5.51 | 3.06±0.25 | < 0.01 | ||
| BV3 | 59.93±5.30 | 2.27±0.45 | 69.67±6.01 | 2.87±0.35 | 79.17±6.54 | 3.17±0.38 | < 0.01 | ||
| CT | 56.17±6.25 | 2.07±0.25 | 68.33±4.61 | 2.93±0.25 | 72.17±5.03 | 2.97±0.18 | < 0.01 | ||
| bP value | >0.05 | >0.05 | >0.05 | >0.05 | <0.05 | <0.05 | |||
| External rotation | |||||||||
| BV1 | 69.53±8.83 | 2.80±0.41 | 79.27±6.78 | 3.17±0.38 | 86.37±3.96 | 3.50±0.51 | < 0.01 | ||
| BV2 | 67.67±4.10 | 2.87±0.35 | 83.50±3.51 | 3.07±0.25 | 88.83±2.52 | 3.80±0.41 | < 0.01 | ||
| BV3 | 67,00±6.10 | 2.73±0.45 | 78,00±6.64 | 3.07±0.25 | 87.50±4.10 | 3.63±0.49 | < 0.01 | ||
| CT | 69.17±4.37 | 2.97±0.18 | 83.50±3.26 | 3.03±0.18 | 87.17±3.13 | 3.50±0.51 | < 0.01 | ||
| bP value | >0.05 | >0.05 | <0.05 | <0.05 | >0.05 | >0.05 | |||
| Shoulder function | |||||||||
| BV1 | 61.70±4.19 | 1.83±0.38 | 74.66±3.65 | 2.73±0.45 | 84.97±4.47 | 3.57±0.50 | < 0.01 | ||
| BV2 | 60.87±4.62 | 1.83±0.38 | 78.57±5.26 | 2.93±0.37 | 89.13±6.51 | 3.73±0.45 | < 0.01 | ||
| BV3 | 61.77±2.99 | 1.93±0.25 | 76,00±2.52 | 2.83±0.38 | 85.60±3.93 | 3.73±0.45 | < 0.01 | ||
| CT | 62.23±5.72 | 1.90±0.40 | 77.80±5.64 | 2.77±0.50 | 86.70±5.88 | 3.60±0.50 | < 0.01 | ||
| bP value | >0.05 | >0.05 | <0.05 | <0.05 | <0.05 | <0.05 | |||
Table 4 Average levels of pro-inflammatory (TNF-α and IL-1β) and anti-inflammatory (IL-10) cytokines among groups at baseline, 10 and 15 days after treatment initiation ($\bar{x}±s$)
| Item | Baseline | 10 d | 15 d | aP value |
|---|---|---|---|---|
| TNF-α | ||||
| BV1 | 311.6±162.7 | 116.4±50.5 | 104.5±31.5 | <0.05 |
| BV2 | 330.6±186.4 | 112.1±53.7 | 81.6±42.3 | <0.01 |
| BV3 | 332.4±159.9 | 100.3±45.8 | 67.7±53.3 | <0.01 |
| CT | 302.5±139.6 | 118.9±36.3 | 89.3±38.3 | <0.05 |
| bP value | >0.05 | >0.05 | <0.05 | |
| IL-1β | ||||
| BV1 | 126.2±63.6 | 101.8±37.7 | 91.5±23.9 | <0.05 |
| BV2 | 122.9±54.0 | 103.4±51.0 | 100.6±41.7 | <0.01 |
| BV3 | 124.7±72.7 | 97.1±49.3 | 94.1±31.9 | <0.01 |
| CT | 128.6±96.4 | 103.8±32.4 | 98.1±22.2 | <0.05 |
| bP value | >0.05 | >0.05 | >0.05 | |
| IL-10 | ||||
| BV1 | 6.2±2.1 | 6.4±1.8 | 6.6±1.5 | >0.05 |
| BV2 | 6.3±1.7 | 6.6±1.8 | 6.9±1.8 | >0.05 |
| BV3 | 6.2±2.0 | 7.2±2.0 | 7.5±1.6 | <0.05 |
| CT | 6.3±2.0 | 6.3±2.0 | 6.2±1.5 | >0.05 |
| bP value | >0.05 | >0.05 | <0.05 | >0.05 |
Table 4 Average levels of pro-inflammatory (TNF-α and IL-1β) and anti-inflammatory (IL-10) cytokines among groups at baseline, 10 and 15 days after treatment initiation ($\bar{x}±s$)
| Item | Baseline | 10 d | 15 d | aP value |
|---|---|---|---|---|
| TNF-α | ||||
| BV1 | 311.6±162.7 | 116.4±50.5 | 104.5±31.5 | <0.05 |
| BV2 | 330.6±186.4 | 112.1±53.7 | 81.6±42.3 | <0.01 |
| BV3 | 332.4±159.9 | 100.3±45.8 | 67.7±53.3 | <0.01 |
| CT | 302.5±139.6 | 118.9±36.3 | 89.3±38.3 | <0.05 |
| bP value | >0.05 | >0.05 | <0.05 | |
| IL-1β | ||||
| BV1 | 126.2±63.6 | 101.8±37.7 | 91.5±23.9 | <0.05 |
| BV2 | 122.9±54.0 | 103.4±51.0 | 100.6±41.7 | <0.01 |
| BV3 | 124.7±72.7 | 97.1±49.3 | 94.1±31.9 | <0.01 |
| CT | 128.6±96.4 | 103.8±32.4 | 98.1±22.2 | <0.05 |
| bP value | >0.05 | >0.05 | >0.05 | |
| IL-10 | ||||
| BV1 | 6.2±2.1 | 6.4±1.8 | 6.6±1.5 | >0.05 |
| BV2 | 6.3±1.7 | 6.6±1.8 | 6.9±1.8 | >0.05 |
| BV3 | 6.2±2.0 | 7.2±2.0 | 7.5±1.6 | <0.05 |
| CT | 6.3±2.0 | 6.3±2.0 | 6.2±1.5 | >0.05 |
| bP value | >0.05 | >0.05 | <0.05 | >0.05 |
| 1. |
Urwin M, Symmons D, Allison T, et al. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. Ann Rheum Dis 1998; 57: 649-55.
DOI PMID |
| 2. | van der Windt DA, Koes BW, Boeke AJ, et al. Shoulder disorders in general practice: prognostic indicators of outcome. Br J Gen Pract 1996; 46: 519-23. |
| 3. |
Oldberg S. On the etiology of periarthritis humero-scapularis. Ups J Med Sci 1972; 77: 143-8.
DOI URL |
| 4. | Cyriax J. Text book of orthopaedics medicine. 2nd ed. London: Baillière Tindall, 1982: 191-258. |
| 5. | Hand GC, Athanasou NA, Matthews T, Carr AJ. The pathology of frozen shoulder. J Bone Joint Surg Br 2007; 89: 928-32. |
| 6. | Dueltgen C, Luessenhop H. Physical therapy in the management of periarthritis humeroscapularis. Arch Phys Ther (Leipz) 1960; 12: 123-6. |
| 7. |
Wagenhauser FJ. Management of the periarthritis-humeroscapularis syndrome. Dtsch Med Wochensch 1969; 94: 1579-81.
DOI URL |
| 8. |
Wang J, Wang W, Wang S. Treatment of periarthritis humeroscapularis with acupuncture and acupoint blocking. J Tradit Chin Med 1993; 13: 262-3.
PMID |
| 9. |
Brien S, Lewith G, Walker A, Hicks SM, Middleton D. Bromelain as a treatment for osteoarthritis: a review of clinical studies. Evid Based Complement Alternat Med 2004; 1: 251-7.
DOI URL |
| 10. |
Niewald M, Fleckenstein J, Naumann S, Ruebe C. Long-term results of radiotherapy for periarthritis of the shoulder: a retrospective evaluation. Radiat Oncol 2007; 2: 34.
PMID |
| 11. |
Kim YS, Jun H, Chae Y, et al. The practice of Korean medicine: an overview of clinical trials in acupuncture. Evid Based Complement Alternat Med 2005; 2: 325-52.
DOI URL |
| 12. |
Lee WR, Pak SC, Park KK. The protective effect of bee venom on fibrosis causing inflammatory diseases. Toxins (Basel) 2015; 7: 4758-72.
DOI URL |
| 13. | Chen J. Spinal processing of bee venom-induced pain and hyperalgesia. Sheng Li Xue Bao 2008; 60: 645-52. |
| 14. |
Koburova KL, Michailova SG, Shkenderov SV. Further investigation on the antiinflammatory properties of adolapin--bee venom polypeptide. Acta Physiol Pharmacol Bulg 1985; 11: 50-5.
PMID |
| 15. |
Park HJ, Son DJ, Lee CW, et al. Melittin inhibits inflammatory target gene expression and mediator generation via interaction with IkappaB kinase. Biochem Pharmacol 2007; 73: 237-47.
PMID |
| 16. |
Shen L, Lee JH, Joo JC, Park SJ, Song YS. Bee venom acup-uncture for shoulder pain: a systematic review and Meta-analysis of randomized controlled trials. J Pharmacopuncture 2020; 23: 44-53.
DOI PMID |
| 17. |
Lim SM, Lee SH. Effectiveness of bee venom acupuncture in alleviating post-stroke shoulder pain: a systematic review and Meta-analysis. J Integr Med 2015; 13: 241-7.
DOI PMID |
| 18. | Lee MS, Pittler MH, Shin BC, Kong JC, Ernst E. Bee venom acupuncture for musculoskeletal pain: a review. J Pain 2008; 9: 289-97. |
| 19. | Sung SH, Lee G. Bee venom acupuncture effects on pain and its mechanisms: an updated review. Toxins (Basel) 2021: 13. |
| 20. |
Koh PS, Seo BK, Cho NS, Park HS, Park DS, Baek YH. Clinical effectiveness of bee venom acupuncture and physiotherapy in the treatment of adhesive capsulitis: a randomized controlled trial. J Shoulder Elbow Surg 2013; 22: 1053-62.
DOI PMID |
| 21. | Constant CR, Murley AH. A clinical method of functional assessment of the shoulder. Clin Orthop Relat Res 1987; 160-4. |
| 22. | Lee SH, Lim SM. Acupuncture for poststroke shoulder pain: a systematic review and Meta-analysis. Evid Based Complement Alternat Med 2016: 3549878. |
| 23. |
Szczudlik A, Lypka A. Plasma concentration of immunoreactive beta-endorphin in healthy persons during pinpoint stimulation of receptors (acupuncture). Neurol Neurochir Pol 1983; 17: 535-40.
PMID |
| 24. |
Peng CH, Yang MM, Kok SH, Woo YK. Endorphin release: a possible mechanism of acupuncture analgesia. Comp Med East West 1978; 6: 57-60.
PMID |
| 25. | Ben-Arie E, Kao PY, Lee YC, Ho WC, Chou LW, Liu HP. The effectiveness of acupuncture in the treatment of frozen shoulder: a systematic review and Meta-analysis. Evid Based Complement Alternat Med 2020: 9790470. |
| 26. |
Asheghan M, Aghda AK, Hashemi E, Hollisaz M. Investigation of the effectiveness of acupuncture in the treatment of frozen shoulder. Mater Sociomed 2016; 28: 253-57.
DOI PMID |
| 27. | Kwon YB, Lee JD, Lee HJ, et al. Bee venom injection into an acupuncture point reduces arthritis associated edema and nociceptive responses. Pain 2001; 90: 271-80. |
| 28. |
Lee JD, Park HJ, Chae Y, Lim S. An overview of bee venom acupuncture in the treatment of arthritis. Evid Based Complement Alternat Med 2005; 2: 79-84.
DOI URL |
| 29. |
Lee JA, Son MJ, Choi J, Jun JH, Kim JI, Lee MS. Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials. BMJ Open 2014; 4: e006140.
DOI URL |
| 30. | Li D, Kim W, Shin D, Jung Y, Bae H, Kim SK. Preventive effects of bee venom derived phospholipase a(2) on oxaliplatin-induced neuropathic pain in mice. Toxins (Basel) 2016; 8. |
| 31. | Ham HJ, Han SB, Yun J, et al. Bee venom phospholipase A2 ameliorates amyloidogenesis and neuroinflammation through inhibition of signal transducer and activator of transcription-3 pathway in Tg2576 mice. Transl Neurodegener 2019; 8: 26. |
| 32. |
Gu SM, Park MH, Hwang CJ, et al. Bee venom ameliorates lipopolysaccharide-induced memory loss by preventing NF-kappa B pathway. J Neuroinflammation 2015; 12: 124.
DOI URL |
| 33. |
Park JH, Kim KH, Kim SJ, Lee WR, Lee KG, Park KK. Effect of bee venom on transforming growth factor-beta1-treated hepatocytes. Int J Toxicol 2010; 29: 49-56.
DOI URL |
| 34. |
Chung HJ, Lee J, Shin JS, et al. In vitro and in vivo anti-allergic and anti-inflammatory effects of eBV, a newly developed derivative of bee venom, through modulation of IRF 3 signaling pathway in a carrageenan-induced edema model. PLoS One 2016; 11: e0168120.
DOI URL |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
